ST. HELIER, JERSEY, 4 September 2015 – Novocure, a commercial stage oncology company, announced today that its ongoing and future clinical trial designs in lung cancer will be presented at the 16th World Conference on Lung Cancer (WCLC). The WCLC is the world’s largest meeting dedicated to lung cancer and other thoracic malignancies, organized by the International Association for the Study of Lung Cancer (IASLC). The meeting will take place in Denver, Colorado from September 6 to 9, 2015.
The data presented will include a preclinical background and the clinical trial design of the following studies testing Tumor Treating Fields (TTFields) in thoracic tumors:
• STELLAR – an ongoing phase II pilot trial of TTFields together with pemetrexed combined with cisplatin or carboplatin in malignant pleural mesothelioma;
Ad Statistics
Times Displayed: 22281
Times Visited: 445 Stay up to date with the latest training to fix, troubleshoot, and maintain your critical care devices. GE HealthCare offers multiple training formats to empower teams and expand knowledge, saving you time and money
• LUNAR – a planned phase III trial of front-line chemotherapy with TTFields for advanced squamous non-small-cell lung cancer (NSCLC); and
• METIS – a planned phase III trial of TTFields following stereotactic radiosurgery (SRS) for 1- 10 brain metastases from NSCLC. The METIS trial follows the ongoing COMET phase II pilot trial for 1-5 brain metastases from NSCLC.
“The preclinical research and clinical research available to date demonstrates that TTFields’ mechanism of action affects fundamental aspects of cell division and could potentially have broad applicability across a variety of solid tumors,” said Minesh Mehta, MD, Medical Director of the Maryland Proton Treatment Center and a radiation oncologist at the University of Maryland. “I am pleased that this novel modality, associated with few side effects to date, is being explored in brain metastases with the METIS trial, as well as in primary lung cancer and mesothelioma.”
“TTFields have already been demonstrated to be safe when applied to the upper torso in a phase II pilot trial for advanced NSCLC,” said Giovanni Luca Ceresoli, MD, Head of Pulmonary Oncology at the Humanitas Gavazzeni Hospital in Bergamo, Italy. “After examining the compelling data obtained through long-term basic research of TTFields in different thoracic malignancies, we are happy to lead the research of this regional therapy in mesothelioma as a part of the STELLAR trial.”
“Novocure has developed a pipeline strategy to advance TTFields through phase II pilot and phase III pivotal clinical trials across multiple solid tumor types,” said Uri Weinberg, MD, PhD, Novocure’s Vice President for Research and Development. “In addition to ongoing trials in pancreatic cancer, ovarian cancer and brain metastases, we are committed to developing TTFields as a potential treatment for thoracic tumors, which unfortunately cause the highest number of cancer-related deaths worldwide.”
